甲氨蝶呤联合生物制剂治疗类风湿关节炎的随机对照试验的实用性:一项系统综述
该系统综述纳入96项随机对照试验,采用PRECIS-2工具从9个维度评估甲氨蝶呤联合生物制剂或靶向合成改善病情抗风湿药治疗类风湿关节炎的实用性。结果显示纳入标准、随访和干预实施灵活性被评为解释性,而环境和主要分析被评为实用性,多数试验(74%)在多数维度上为解释性,可能影响结果向临床实践的外推。
要点
- 纳入标准、随访和干预灵活性平均PRECIS-2评分分别为2.0±0.7、2.0±1.1和2.1±0.7,反映严格纳入、密集随访和刚性方案。
- 环境和主要分析维度平均评分分别为3.6±1.5和4.1±1.3,因多为国际多中心试验且多数采用意向性治疗分析。
- 潜类别分析识别2组,多数(74%)在多数评估维度上为解释性,这些试验样本量更大、更可能由企业资助。
核心结论
- 甲氨蝶呤联合生物制剂治疗类风湿关节炎的随机对照试验主要被评为解释性,可能影响试验结果向临床实践的外推。
研究设计与样本
- 系统综述纳入96项随机对照试验,比较生物制剂或靶向合成改善病情抗风湿药联合甲氨蝶呤与安慰剂或任何其他改善病情抗风湿药,采用PRECIS-2工具从9个维度评分(1分=非常解释性,5分=非常实用性),并进行潜类别和回归分析。
主要发现
- 纳入标准、随访和干预实施灵活性维度平均±标准差PRECIS-2评分分别为2.0±0.7、2.0±1.1和2.1±0.7。
- 环境和主要分析维度平均±标准差评分分别为3.6±1.5和4.1±1.3。
- 潜类别分析识别2组,多数(74%)在多数评估维度上为解释性,这些试验样本量更大、更可能由企业资助、纳入患者28关节疾病活动度评分和健康评估问卷残疾指数更高,但高偏倚风险可能性更低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Randomized controlled trials (RCTs) exist along a spectrum, from explanatory, designed to evaluate interventions under ideal conditions, to pragmatic, designed to reflect usual care. This study assessed the pragmatism of RCTs of advanced therapeutics in rheumatoid arthritis (RA). METHODS: A systematic review was conducted to identify RA RCTs comparing biologic or targeted synthetic therapy in combination with methotrexate, to placebo or any other disease-modifying antirheumatic drugs (DMARDs). Trials were rated using the Pragmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) tool in 9 domains, each rated from 1 (very explanatory) to 5 (very pragmatic). Latent class and regression analyses examined the heterogeneity in PRECIS-2 scores and the relationship to trial characteristics. RESULTS: In total, 96 trials were included. Eligibility, follow-up, and flexibility of delivery of the intervention were rated as explanatory, with mean ± SD PRECIS-2 scores of 2.0 ± 0.7, 2.0 ± 1.1, and 2.1 ± 0.7, respectively, reflecting strict inclusion criteria, intensive follow-up, and rigid protocols. Studies were rated as pragmatic in setting (3.6 ± 1.5) because many were international, multicenter trials, and in primary analysis (4.1 ± 1.3), because most used intent-to-treat analyses. In latent class analyses, 2 groups were identified; the majority (74%) were rated as explanatory for most domains assessed. These trials had larger sample sizes, were more likely to be industry-funded, and enrolled patients with higher Disease Activity Score in 28 joints and Health Assessment Questionnaire disability index scores, but were less likely to be at high risk of bias. CONCLUSION: RCTs of biologic DMARD treatment in combination with methotrexate for RA were rated as predominantly explanatory, which may affect the generalizability of trial results to clinical practice.
引用
- Choi MY, Barnabe C, Barber CE, et al. Pragmaticism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken). 2019. PMID: 29908014. doi:10.1002/acr.23620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。